Skip to main content
Premium Trial:

Request an Annual Quote

Lumera's Q4 Revenues Dip, Net Loss Rises

NEW YORK (GenomeWeb News) – Lumera reported after the close of the market yesterday that its fourth-quarter revenues fell 72.7 percent and its net loss increased 64.5 percent as a government contract wrapped up in the early part of the quarter.
Lumera had revenues of $356,000 for the three-month period ended Dec. 31, 2007, compared to revenues of $1.2 million in the fourth quarter of 2006. Revenue from a government contract was $320,000 in the quarter. The firm said that the decline in revenue was expected and is related to the timing of milestones under a contract with the Defense Advanced Research Projects Agency, which finished early in the fourth quarter.
Bothell, Wash.-based Lumera posted a net loss of $5.1 million, or $.25 per share, compared to a net loss of $3.1 million, or $.17 per share, in the comparable period of 2006.
The firm’s R&D expenses rose 23.8 percent to $2.6 million from $2.1 million, and its SG&A costs climbed 55.6 percent to $2.8 million from $1.8 million.
For full-year 2007, Lumera reported revenues of $2.8 million compared to $3.4 million in 2006. Its net loss increased to $16 million, or $.80 per share, from $12.1 million, or $.70 per share.
Lumera’s R&D spending for the year was $7.3 million, up from 6.7 million, while SG&A costs jumped to $11 million from $7.7 million.
The firm finished the year with $7.1 million in cash and cash equivalents.
Lumera expects contract revenues in 2008 to be around $6 million, compared with $2.6 million realized in 2007.
The firm’s Plexera Bioscience subsidiary announced during the fourth quarter that it had signed an agreement with an undisclosed early-access customer for its antibody discovery system, which Plexera expects to launch in May 2008.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.